Introduction: We evaluated the efficacy and tolerability of 3- and 6-month leuprorelin acetate (LA) depot formulations (Eligard®, Astellas Pharma GmbH) in patients with advanced prostate cancer treated in routine clinical practice in Germany. Materials and Methods: Data was pooled from 2 prospective, open-label, non-interventional studies in which 1,906 patients were treated for 12 months with either the 3-month (n = 633) or 6-month (n = 1,273) LA formulation. Results: Median prostate-specific antigen levels in the pooled patient population declined from 12.0 ng/mL at baseline to 0.5 ng/mL after 12 months. Prostate-specific antigen reduction was achieved in treatment-naïve and pre-treated patients. Adverse events were documented in 8.8% of patients. Conclusions: These pooled data from routine clinical practice in Germany indicate that LA 3- and 6-month depot injections can effectively reduce prostate-specific antigen levels in a broad patient population with advanced prostate cancer.

Keywords:
Eligard®, Leuprolide, Non-interventional studies, Prospective study on cancer
1.
Robert Koch-Institut: [Cancer in Germany 2011/2012]. http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2015/krebs_in_deutschland_2015.pdf?__blob=publicationFile. Last Updated August 10, 2015 (accessed April 20, 2016).
2.
Huggins C, Stevens RE Jr, Hodges CV: Studies on prostatic cancer II: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–223.
3.
Huggins C, Hodges CV: Studies on prostatic cancer I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–297.
4.
Porcaro AB, Petroziello A, Brunelli M, De Luyk N, Cacciamani G, Corsi P, Sebben M, Tafuri A, Tamanini I, Caruso B, Ghimenton C, Monaco C, Artibani W: High testosterone preoperative plasma levels independently predict biopsy Gleason score upgrading in men with prostate cancer undergoing radical prostatectomy. Urol Int 2016; 96: 470–478.
5.
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A: EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572–583.
6.
Mottet N, Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P, De Santis M, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Arfi N, van den Bergh RCN, van den Broeck T, Cumberbatch M, Fossati N, Gross T, Lardas M, Liew M, Moldovan P, Schoots IG, Willemse PM: European Association of Urology. Guidelines on Prostate Cancer. http://uroweb.org/guideline/prostate-cancer/. Last updated March 2016 (accessed February 28, 2017).
7.
Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC: A clinical study of 22.5 mg. La-2550:A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002; 168: 1199–1203.
8.
Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS: A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006; 175: 533–536.
9.
Perez-Marreno R, Chu FM, Gleason D, Loizides E, Wachs B, Tyler RC: A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002; 24: 1902–1914.
10.
Tunn UW: A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urol 2011; 11: 15.
11.
Ouzaid I, Roupret M: [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the “ELIRE” observational study]. Prog Urol 2011; 21: 866–874.
12.
Braeckman J, Michielsen D: Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo-Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study. Arch Med Sci 2014; 10: 477–483.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.